Inventor · disambiguated record
Jonathan Belk
Also filed as: BELK JONATHAN · BELK JONATHAN P · BELK JONATHAN PHILIP
28 granted patents·14 pending applications·240 citations·filing 2004–2024
96Inventor score
Files withACCELERON PHARMA INC11KITE PHARMA INC6ABBVIE INC5ADAGIO THERAPEUTICS INC4CHECKPOINT THERAPEUTICS INC3
Top patents by PatentIndex Score
42 records- 0197US7915388B2Interleukin-13 binding proteinsABBOTT LAB·Filed 2007·Granted Mar 29, 2011·96 cites·41 claims
- 0295US7700739B2IL-12/p40 binding proteinsABBOTT LAB·Filed 2006·Granted Apr 20, 2010·57 cites·117 claims
- 0393US11192940B2Compounds specific to coronavirus S protein and uses thereofADAGIO THERAPEUTICS INC·Filed 2021·Granted Dec 7, 2021·10 cites·14 claims
- 0492US9592293B2Interleukin-13 binding proteinsABBVIE INC·Filed 2013·Granted Mar 14, 2017·18 cites·13 claims
- 0591US10882915B2Compositions and methods for the depletion of CD117+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Jan 5, 2021·9 cites·27 claims
- 0690US10501547B2ALK7 binding proteins and uses thereofACCELERON PHARMA INC·Filed 2017·Granted Dec 10, 2019·3 cites·7 claims
- 0789US11572411B2Anti-CD117 antibodies and conjugatesMAGENTA THERAPEUTICS INC·Filed 2020·Granted Feb 7, 2023·2 cites·14 claims
- 0889US8629257B2IL-12/p40 binding proteinsLACY SUSAN E·Filed 2010·Granted Jan 14, 2014·18 cites·33 claims
- 0987US11344621B2Interleukin-13 binding proteinsABBVIE INC·Filed 2018·Granted May 31, 2022·2 cites·35 claims
- 1087US10307455B2Activin type 2 receptor antibodiesACCELERON PHARMA INC·Filed 2017·Granted Jun 4, 2019·5 cites·14 claims
- 1186US11414479B2Compounds specific to coronavirus S protein and uses thereofADAGIO THERAPEUTICS INC·Filed 2021·Granted Aug 16, 2022·1 cites·13 claims
- 1286US11220536B1Compounds specific to coronavirus S protein and uses thereofADAGIO THERAPEUTICS INC·Filed 2021·Granted Jan 11, 2022·1 cites·23 claims
- 1386US10086076B2Interleukin-13 binding proteinsABBVIE INC·Filed 2017·Granted Oct 2, 2018·4 cites·11 claims
- 1485US2024374671A1Activin Type 2 Receptor Binding Proteins and Methods of Making ThemACCELERON PHARMA INC·Filed 2024·Application pending·0 cites
- 1584US9200270B2Methods for transforming yeastHSIEH CHUNG-MING·Filed 2009·Granted Dec 1, 2015·4 cites·15 claims
- 1683US11059894B2ALK7 binding proteins and uses thereofACCELERON PHARMA INC·Filed 2019·Granted Jul 13, 2021·1 cites·7 claims
- 1783US10590199B2PD-L1-specific antibodies and methods of using the sameCHECKPOINT THERAPEUTICS INC·Filed 2017·Granted Mar 17, 2020·3 cites·31 claims
- 1882US2023416379A1ALK7 Binding Proteins and Uses ThereofACCELERON PHARMA INC·Filed 2023·Application pending·0 cites
- 1979US10689450B2BCMA binding molecules and methods of use thereofKITE PHARMA INC·Filed 2017·Granted Jun 23, 2020·1 cites·71 claims
- 2078US8604177B2Interleukin-13 binding proteinsWU CHENGBIN·Filed 2011·Granted Dec 10, 2013·3 cites·30 claims
- 2177US11708414B2ALK7 binding proteins and uses thereofACCELERON PHARMA INC·Filed 2021·Granted Jul 25, 2023·0 cites·7 claims
- 2276US12042524B2Activin type 2 receptor binding proteins methods of making themACCELERON PHARMA INC·Filed 2021·Granted Jul 23, 2024·0 cites·15 claims
- 2375US11793834B2Chimeric antigen and T cell receptors and methods of useKITE PHARMA INC·Filed 2019·Granted Oct 24, 2023·1 cites·17 claims
- 2475US11485795B2Anti-PCSK9 antibody and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2017·Granted Nov 1, 2022·1 cites·29 claims
- 2575US2024287196A1ALK7 Binding Proteins and Uses ThereofACCELERON PHARMA INC·Filed 2024·Application pending·0 cites
- 2674US2024115611A1Chimeric antigen and t cell receptors and methods of useKITE PHARMA INC·Filed 2023·Application pending·0 cites
- 2774US2024150468A1Pd-l1-specific antibodies and methods of using the sameCHECKPOINT THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2873US2023146195A1Bcma binding molecules and methods of use thereofKITE PHARMA INC·Filed 2022·Application pending·0 cites
- 2971US11505613B2BCMA binding molecules and methods of use thereofKITE PHARMA INC·Filed 2019·Granted Nov 22, 2022·0 cites·22 claims
- 3071US11000565B2Methods of increasing muscle mass by administration of activin type 2 receptor antibodiesACCELERON PHARMA INC·Filed 2019·Granted May 11, 2021·0 cites·10 claims
- 3171US2022153815A1Compounds specific to coronavirus s protein and uses thereofADAGIO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3264US11834505B2PD-L1-specific antibodies and methods of using the sameCHECKPOINT THERAPEUTICS INC·Filed 2020·Granted Dec 5, 2023·0 cites·31 claims
- 3361US11981738B2ALK7 binding proteins and uses thereofACCELERON PHARMA INC·Filed 2018·Granted May 14, 2024·0 cites·11 claims
- 3456US2014178332A1IL-12/p40 BINDING PROTEINSABBVIE INC·Filed 2014·Application pending·0 cites
- 3552US12365736B2ALK7 binding proteins and uses thereofACCELERON PHARMA INC·Filed 2020·Granted Jul 22, 2025·0 cites·20 claims
- 3652US2005227289A1Antibodies to erythropoietin receptor and uses thereofREILLY EDWARD B·Filed 2004·Application pending·0 cites
- 3750US2016153001A1Methods for transforming yeastABBVIE INC·Filed 2015·Application pending·0 cites
- 3848US12337035B2TACI binding moleculesKITE PHARMA INC·Filed 2022·Granted Jun 24, 2025·0 cites·24 claims
- 3948US2025059258A1Ch1 domain affinity ligands and agentsAvitide LLC·Filed 2022·Application pending·0 cites
- 4044US2008038265A1Antibodies to Erythropoietin Receptor and Uses ThereofREILLY EDWARD B·Filed 2006·Application pending·0 cites
- 4140US2006018902A1Antibodies to erythropoietin receptor and uses thereofREILLY EDWARD B·Filed 2005·Application pending·0 cites
- 4234US2024236347A9Aav2 affinity agentsAvitide LLC·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jonathan Belk files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →